Last reviewed · How we verify

NCT03098043

Post-Static Cold Storage Hypothermic Oxygenated Perfusion in Bergamo Liver Transplant Program

Status unknown Last updated 26 November 2019
What this trial tests

trial in Liver Transplantation in 20 participants. Status unknown.

Timeline
5 November 2017
Primary endpoint
3 December 2021
3 December 2021

Quick facts

Lead sponsorPapa Giovanni XXIII Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date5 November 2017
Primary completion3 December 2021
Estimated completion3 December 2021
Sites1 location across Italy

Conditions studied

Sponsor

Papa Giovanni XXIII Hospital

Who can join

Adults 30 Days to 70, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In light of the widespread organ shortage, dynamic preservation by means of Machine Perfusion (MP) has been proposed as a strategy to increase the pool of suitable grafts for liver transplantation. Reproducing more physiological conditions than traditional Static Cold Storage (SCS), MP may allow a better preservation and evaluation and perhaps even the resuscitation of high risk grafts. As a consequence, unnecessary discard of organs could be avoided and quality and safety of transplantation could be improved as well. Hypothermic MP (HMP) seems to reduce ischemia-reperfusion injury. In fact, hypothermia slows down the metabolic rate and the oxygenation of the perfusate leads to re-synthesis of Adenosine TriPhosphate (ATP), which results in the restoration of cellular energy. Four series about the use of HMP in the clinical setting has been published so far. They all report acceptable outcomes after transplantation of human liver grafts from extended criteria Brain Dead Donors (BDD) and from Donation after Circulatory Death (DCD) donors preserved by HMP, thus proving its feasibility and safety. The efficacy of HMP, instead, is still under investigation in a phase II randomized trial. This is an observational, prospective, monocentric study aiming at verifying the feasibility and safety of post-SCS Hypothermic Oxygenated PErfusion (HOPE) in the setting of our liver transplant program. Extended criteria grafts from BDD and grafts from DCD donors will be preserved by post-SCS HOPE prior to transplantation. The recipients of these grafts will be followed-up for at least 1 year.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD).
    Czigany Z, Schöning W, Ulmer TF, Bednarsch J, et al · · 2017 · cited 56× · PMID 29018070 · DOI 10.1136/bmjopen-2017-017558

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Papa Giovanni XXIII Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03098043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing